Compare EFOI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | CMMB |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 19.9M |
| IPO Year | 2004 | 2023 |
| Metric | EFOI | CMMB |
|---|---|---|
| Price | $2.84 | $2.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 5.4K | ★ 104.2K |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.75 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $3,560,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $67.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.66 | $1.35 |
| 52 Week High | $9.84 | $3.55 |
| Indicator | EFOI | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 65.37 |
| Support Level | $2.83 | $1.49 |
| Resistance Level | $3.00 | $2.86 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 44.83 | 62.13 |
Energy Focus Inc specializes in designing, developing, manufacturing, and selling energy-efficient lighting systems and controls. It provides LED lighting solutions for both commercial and military maritime markets (MMM). Its core products include robust lighting fixtures and lamps for navy and military applications, Energy Storage Systems (ESS), Uninterruptible Power Supply (UPS), and tubular LED (TLED) lighting products, including battery backup units as well as general commercial and maritime lighting fixtures. The company operates in a single business segment that includes the marketing and sale of commercial and MMM lighting products and controls. The company generates a majority of its revenue from the sales of military maritime products in the United States.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.